Study guide

3.3 DSCSA & Drug Supply Chain Integrity

New York MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the NY MPJE Exam 1.2 Study Strategy & Federal vs. New York Law Hierarchy

2 Federal Pharmacy Law: Controlled Substances

2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Registration, Forms & Security 2.3 Federal Food, Drug, and Cosmetic Act (FDCA)

3 Federal Pharmacy Law: Privacy & Supply Chain

3.1 HIPAA & Patient Privacy 3.2 OBRA '90, Medicare/Medicaid & DUR 3.3 DSCSA & Drug Supply Chain Integrity

4 Area 1a: NYSED, Board & Pharmacist Licensure

4.1 NYSED Office of the Professions, Board of Pharmacy & Education Law Article 137 4.2 Pharmacist Licensure: Education, NAPLEX/MPJE & Internship 4.3 License by Endorsement, Renewal & Continuing Education

5 Area 1b: Interns, Technicians & Discipline

5.1 Pharmacy Interns & Limited Permits 5.2 Registered Pharmacy Technicians (RPhT) & Supervision Ratios 5.3 Professional Misconduct, Discipline & Impaired Practitioner Programs

6 Area 2a: Prescribing, Controlled Substances & Collaborative Practice

6.1 Prescription Requirements & Practitioner Authority 6.2 Controlled Substance Prescribing & the NY EPCS Mandate 6.3 Refills & Authority Limitations 6.4 Collaborative Drug Therapy Management (§6801-a) & Non-Patient-Specific Orders

7 Area 2b: Counseling, Immunization & Public Health

7.1 Patient Counseling & Documentation 7.2 Pharmacist Immunization Authority 7.3 Naloxone Access & Public Health Programs 7.4 Patient Confidentiality & Pharmacy Records

8 Area 3a: Verification, Transfers & DUR/I-STOP

8.1 Legitimate Medical Purpose & Corresponding Responsibility 8.2 Prescription Transfers Between Pharmacies 8.3 Prospective DUR & the I-STOP PMP Registry 8.4 Refill Exceptions & Emergency Dispensing

9 Area 3b: Labeling, Packaging & Substitution

9.1 Labeling of Dispensed Drugs 9.2 Packaging: PPPA & Child-Resistant Containers 9.3 Generic Substitution & Interchangeable Biologics (§6816-a) 9.4 OTC, Behind-the-Counter & Restricted Nonprescription Sales

10 Area 4a: Records, Inventories & Delivery

10.1 Ordering, Acquisition & Distribution Records 10.2 Recordkeeping, Storage & Handling 10.3 Controlled Substance Inventories & BNE Registration 10.4 Delivery & Mail-Order Dispensing

11 Area 4b: Compounding, Central Fill & Facilities

11.1 Compounding: Non-Sterile, Sterile & Hazardous Drugs 11.2 Central Fill, Centralized Processing & Shared Pharmacy Services 11.3 Automated Dispensing & Telepharmacy 11.4 Pharmacy Establishment Registration, Inspections & Discipline

12 Test-Day Strategy & Final Review

12.1 When New York Law Is Stricter Than Federal Law 12.2 Test-Day Strategy & Common Traps

3.3 DSCSA & Drug Supply Chain Integrity

Key Takeaways Explain This Topic AI

The Drug Supply Chain Security Act (DSCSA), Title II of the Drug Quality and Security Act of 2013, requires an interoperable, package-level electronic system to trace prescription drugs through the U.S. supply chain.

DSCSA trading partners are manufacturers, wholesale distributors, third-party logistics providers (3PLs), and dispensers (including pharmacies); each must be licensed or registered and may deal only with other authorized trading partners.

Every change of ownership of a covered product must carry Transaction Information and a Transaction Statement (defined at 21 U.S.C. Section 360eee); FDA says the requirement to provide and receive Transaction History effectively ended on November 27, 2023.

FDA's DSCSA stabilization period for full electronic tracing ended November 27, 2024; a separate small dispenser exemption (owning company with 25 or fewer full-time pharmacists and pharmacy technicians) from certain enhanced requirements runs until November 27, 2027.

A pharmacy that confirms a product is illegitimate must quarantine it and notify FDA and the immediate trading partner within 24 hours of confirmation.

Last updated: November 2026

DSCSA & Drug Supply Chain Integrity

The Drug Supply Chain Security Act (DSCSA) , enacted in 2013 as Title II of the Drug Quality and Security Act, directs FDA to build an interoperable, electronic, package-level system for tracing prescription drugs through the U.S. supply chain. The statute's purpose is to detect and remove suspect and illegitimate products — counterfeit, diverted, stolen, intentionally adulterated, or otherwise unfit for distribution — before they reach patients. Every MPJE tests the DSCSA as baseline federal supply-chain law that a New York pharmacy operates under in addition to state wholesale distributor and pedigree rules covered separately.

Trading Partners

DSCSA defines four categories of trading partners , each of which must be properly licensed or registered, and each of which may lawfully transact only with other authorized trading partners:

Trading Partner Role Authorization

Manufacturer Holds an approved NDA/ANDA/BLA or otherwise manufactures the product FDA registration and drug listing

Wholesale distributor Distributes prescription drugs to persons other than the consumer State wholesale distributor license

Third-party logistics provider (3PL) Provides warehousing/distribution logistics on behalf of a manufacturer or distributor, without taking ownership State license; not FDA-registered as a manufacturer

Dispenser Dispenses prescription drugs to patients — pharmacies and prescribers who dispense State pharmacy permit/license; DEA registration for controlled substances

A pharmacy is a dispenser . Buying product from an unlicensed source — an unauthorized online seller, an unlicensed reverse distributor, or another pharmacy outside a recognized exception — violates DSCSA regardless of the product's actual authenticity.

Product Tracing: TI and TS (formerly the "T3")

DSCSA requires each change of ownership of a covered product to be accompanied by product tracing information , defined at 21 U.S.C. § 360eee (older materials call it the "T3"). FDA says that beginning November 27, 2023, the requirement for trading partners to provide and receive transaction history effectively ended, so TI and TS are exchanged today:

Transaction Information (TI) — product name, strength, dosage form, NDC, container size and count, lot number, and the names/addresses of the transferring and receiving trading partners.

Transaction History (TH) — the complete chain of prior transactions for the product, going back to the manufacturer; no longer required since November 27, 2023.

Transaction Statement (TS) — a statement by the transferring entity that it is an authorized trading partner, received the product from an authorized trading partner, did not knowingly ship a suspect or illegitimate product, had systems to comply with verification requirements, and did not knowingly falsify or alter the transaction history.

Since the close of FDA's stabilization period, this data must move electronically between trading partners (for example, EPCIS-based data tied to a package-level 2D barcode) rather than on paper alone.

Dispenser (Pharmacy) Obligations on Receipt

A pharmacy receiving a DSCSA-covered product must:

Confirm the seller is an authorized trading partner .

Receive TI and TS prior to, or at the time of, the transaction.

Not accept product if required tracing data is missing — quarantine or return the product and obtain the missing information before dispensing.

Retain tracing data for six years .

Maintain a system to identify, investigate, and respond to suspect products .

Suspect and Illegitimate Product Handling

A suspect product is one the pharmacy has reason to believe may be counterfeit, diverted, stolen, intentionally adulterated, the subject of a fraudulent transaction, or otherwise unfit for distribution. An illegitimate product is one confirmed , after investigation, to actually be one of those things. The required workflow:

Quarantine the suspect product so it cannot be dispensed.

Investigate — check TI/TS, examine packaging and the 2D barcode, contact the trading partner, and check the NDC and lot against manufacturer records.

If confirmed illegitimate — notify FDA and the immediate trading partner within 24 hours of confirmation (FDA Form 3911, submitted through the CDER NextGen 3911 platform or by email, is the standard notification channel).

If cleared — document the investigation and release the product.

Implementation Status: Stabilization Period and Small Dispenser Exemption

FDA's original DSCSA statutory deadline for full electronic, interoperable, package-level tracing was November 27, 2023. FDA granted a one-year stabilization period — through November 27, 2024 — during which it exercised enforcement discretion over the enhanced drug distribution security requirements of Section 582(g)(1) of the FD&C Act while trading partners matured their systems. That stabilization period has ended , and enhanced electronic tracing requirements now generally apply across the supply chain.

FDA separately granted small dispensers — pharmacies whose owning corporate entity has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians — an exemption from certain Section 582(g)(1) enhanced requirements. The exemption granted in July 2024 ran through November 27, 2026; FDA's August 6, 2026 notice extended it until November 27, 2027 , counting staff as of November 27, 2026. This exemption narrows a specific set of enhanced obligations; it does not eliminate a small dispenser's baseline duties to buy only from authorized trading partners, receive TI and TS, and investigate suspect products.

Exam Traps

Missing tracing data on receipt means quarantine or return — never dispense first and request the paperwork later.

The 24-hour notification clock for a confirmed illegitimate product starts at the moment of confirmation, not the next business day.

Small dispenser status depends on corporate-level pharmacist/technician headcount (25 or fewer full-time), not an individual store's staffing.

The small dispenser exemption is partial and time-limited (until November 27, 2027) — it is not a blanket DSCSA exemption.

Six-year tracing-data retention is a DSCSA-specific rule and may exceed the general pharmacy record retention period found in state law.